Investing

Lyell Immunopharma : LYEL

LYEL

Stock Data

$14.71

$0.50 (3.52%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Lyell Immunopharma Inc is a pioneering force in the field of cell therapy, focusing on the development of innovative treatments for patients with solid tumors. By leveraging cutting-edge genetic and epigenetic reprogramming technologies, the company aims to create more effective and durable T cell therapies. Its product pipeline includes LYL797 and LYL845, both in Phase 1 clinical trials, and LYL119 in preclinical development, targeting a range of solid tumors with enhanced potency. Based in South San Francisco, California, Lyell Immunopharma also collaborates with notable institutions and companies to advance its research and potential therapies.

All Lyell Immunopharma Articles

2 Articles

Lee Jackson | Yesterday

Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while…

Joshua Rodriguez | Aug 30, 2024 at 10:20 AM EDT

3 Penny Stocks to Buy With $500

Are you interested in investing in penny stocks? Though doing so does come with risk, making the right investment decisions…